|Home | About | Journals | Submit | Contact Us | Français|
PREX2 is a PTEN interacting protein that is significantly mutated in melanoma and pancreatic ductal adenocarcinoma. Recently, we reported the mechanistic basis of melanomagenesis by PREX2 mutations. Truncating PREX2 mutations activate its guanine nucleotide exchange factor activity for its substrate RAC1. This leads to increased PI3K/AKT signaling associated with reduced DNA methylation and increased cell proliferation in NRAS-mutant melanoma. Here, we provide additional data that indicates a reciprocal regulation of PREX2 by PTEN whereby loss of PTEN results in a dramatic increase in expression of PREX2 at the protein level. Pharmacologic studies revealed destabilization of PREX2 by inhibition of PI3K/AKT signaling. Additionally, we provide data to show a selective decrease in a particular histone mark, H4 Lys20 trimethylation, in cells expressing PREX2 E824* truncating mutation globally and at the imprint control region of CDKN1C (also known as p57) and IGF2. The decrease in H4K20 trimethylation coupled with DNA hypomethylation at this particular locus is associated with genomic imprinting and regulation of expression of p57 and IGF2. Taken together, these results demonstrate the complex signaling mechanisms that involve PREX2, PI3K/AKT/PTEN and downstream epigenetic machinery to deregulate expression of key cell cycle regulators.
Recent next generation DNA sequencing of tumors have provided insight into the complexity of somatic mutations and given us a compendium of novel significantly mutated cancer genes.1 It is expected that functional genomic studies will provide detailed molecular and functional roles for these mutations in tumor development. We identified PREX2 (phosphatidylinositol-3, 4, 5-triphosphate-dependent Rac-exchange factor 2) as being significantly mutated in human melanomas.2 Interestingly, the International Cancer Genomics Consortium (ICGC) recently reported that PREX2 is also significantly mutated in pancreatic ductal adenocarcinoma.3
PREX2 is a guanine nucleotide exchange factor (GEF) for RAC1 and is a known PTEN binding protein.4,5 Mechanistically, PREX2 has been shown to regulate RAC1 mediated cellular invasion in a manner that cross-talks with PTEN signaling and also regulates insulin signaling and glucose homeostasis through the PI3K pathway.6,7 Initial melanoma genome sequencing studies showed various patterns of PREX2 mutations including missense and truncating mutations. Using xenograft models, we were able to show that truncating PREX2 mutations have oncogenic activity.2 However, the exact mechanism behind PREX2 mutations driven melanoma development was unclear.
To study PREX2 mutations in a tissue and time restricted manner, we generated an inducible transgenic mouse model that expresses a truncating PREX2 mutant (TetO-lox-STOP-lox-PREX2E824*) in melanocytes.8 We crossed these transgenic mice with mice that have a melanoma sensitizing background, i.e. lack the tumor suppressor Ink/Arf and inducibly express a constitutively active NRASQ61K to generate a genetically engineered mouse (GEM) model of melanoma. Tumor formation was induced by administration of tamoxifen (which induces cre mediated recombination and removal of the stopper cassette) and doxycycline (which allows expression of PREX2E824% and NRASQ61K transgenes from tet-responsive promoters). Interestingly, we observed increased incidence of melanoma formation in mice harboring the inducible PREX2 transgene. We also generated xenograft tumors by expressing control GFP, PREX2 wild type or various PREX2 truncating mutations in primary immortalized melanocytes. Again, truncating PREX2 mutations induced increased tumor formation. To explore the molecular mechanisms behind the ability of PREX2 mutations to induce increased tumor formation, we performed gene expression profiling of tumors from both xenograft and GEM models. Integrative cross-species analysis revealed regulations of cell cytoskeleton organization, cell cycle and ribosome biogenesis as key biological pathways to be significantly enriched in tumors having PREX2 truncating tumors. The connection of PREX2 to RAC1 can explain the changes in cell cytoskeleton signaling pathway while the known role of PREX2 in PTEN biology is expected to explain the enrichment in ribosome biogenesis. However, it was not clear why cell cycle regulation is perturbed in PREX2 mutant tumors and we investigated this aspect further.
Histologically, we saw that PREX2 mutant tumors are highly proliferative and show increased Ki67 (a commonly used marker of proliferating cells) staining. Further, we observed reduced expression of key negative cell cycle regulators such as CDKN1C (also known as p57) and CDKN1B (also known as p27) and increased IGF2 (insulin like growth factor 2) in PREX2 mutant tumors. So, how are truncating mutations in PREX2 resulting in these biological changes? To answer this question, we next studied the biochemical and signaling consequences of truncating PREX2 mutations. First, we purified recombinant full length PREX2 or an N-terminal truncated PREX2 (M1-R363) from Sf9 cells and performed guanine nucleotide exchange (GEF) activity assays using RAC1 as a substrate. This revealed higher GEF activity of the truncated PREX2 compared to full length PREX2. In support of this data, we also showed that cells having PREX2 truncating mutation (K278*, E824* and Q1430*) have increased GEF activity as demonstrated by increased GTP loaded RAC1.
What is the molecular basis for the increased GEF activity of truncated PREX2? Our results suggest the existence of at least 2 cooperating mechanisms to account for this. First, truncating PREX2 mutations do not bind to PTEN which is known to have inhibitory effect on the GEF activity of PREX2.6 Hence, by avoiding the inhibitory influence of PTEN, PREX2 mutants have an intrinsically higher GEF activity. Second, using structural modeling of PREX2:RAC1 interaction, we demonstrated that the GEF domain of PREX2 behaves similar to the GEF domain of PREX1. It is known that the C-terminus of PREX1 has an auto-inhibitory role on its N-terminal GEF activity.9,10 Our structural model suggests that a similar mechanism exists in PREX2 and PREX2 truncating mutations relieve the auto-inhibition of GEF activity by the C-terminus. Next we asked what the consequences of increased PREX2 GEF activity and RAC1 activation are. Using reverse phase protein array (RPPA) and immunoblotting, we observed increased phosphorylation of AKT at Ser473 and Thr308 in PREX2 mutant tumors. Gain-of-function and loss-of-function experiments revealed that the increased activation of AKT by PREX2 mutations was dependent on activation of RAC1. This is in line with earlier studies that demonstrated RAC1 can directly bind and activate PI3K.11-13 This mechanism adds another layer of complexity in Rac1-PI3K interaction which is known to involve complex feedback loops including actin cytoskeletal and local phosphorylated lipid changes to sustain activation of the pathway.14
Next we wondered whether the PI3K/AKT pathway in turn exerts any regulatory effects on PREX2. To answer this, we first utilized mouse embryonic fibroblasts (MEFs) isolated from Rosa26-CreERT2 and PTENL/L double positive mice. Introduction of 4-hydroxytamoxifen to these cells activated Cre resulting in genomic recombination, depletion of PTEN and activation of the PI3K/AKT signaling pathway. Interestingly, we observed a dramatic increase in PREX2 protein expression upon acute depletion of PTEN in primary MEFs in vitro (Fig. 1A). This increase in PREX2 protein expression was not associated with an increase in mRNA expression, suggesting post-transcriptional mechanisms such as protein stability are responsible for the observation (Fig. 1B). In line with this observation, inhibition of phosphoinositide-3 (PI3) kinase signaling with pan-PI3 kinase inhibitor (NVP-BKM120) or a dual PI3K/mTOR inhibitor (NVP-BEZ235) led to dose dependent reduction in PREX2 expression (Fig. 1C). Importantly, the reduction in PREX2 protein induced by PI3K inhibitor BKM120 was rescued by co-treatment of cells with the proteasome inhibitor MG132 further supporting the notion that the primary regulatory mechanism of PREX2 expression is at the level of protein stability or translation (Fig. 1D). Taken together, these results show the presence of a reciprocal interplay between PREX2 and the PI3K pathway whereby PREX2 truncating mutations activate the PI3K pathway and activation of the PI3K pathway in turn results in stabilization of PREX2. This interplay is expected to amplify signaling once initiated.
Finally, we investigated how changes in upstream signaling events are related to changes in gene expression regulation. As we have observed strong downregulation of p57 and upregulation of IGF2, we used the gene expression regulation of these genes as read outs to investigate the molecular mechanisms of their perturbation in PREX2 mutant tumors. In our published report, we showed that PREX2 mutation or PTEN deletion induces DNA hypomethylation at the critical imprint control region of p57 and IGF2 which has the well-known effect of downregulating p57 and upregulating IGF2.15-17
Here, we provide further information that support these observations. First, we performed global chromatin immunoprecipitation and sequencing (ChIP-Seq) analysis of an additional epigenetic regulatory mark which is implicated in regulation of genomic imprinting, i.e Histone H4 lysine 20 methylation.16,18,19 We investigated all 3 possible methylation marks, (H4K20) mono-(Me1), di-(Me2) and tri-methylation (Me3), in primary immortalized melanocytes. We observed significant global reduction in H4K20Me3, but not in H4K20Me1 and Me2, in cells expressing PREX2 mutants as compared to GFP control and wildtype PREX2 (Fig. 2A–C). Analysis of H4K20Me3 ChIP-seq profile using a peak-calling algorithm, Scripture,20 showed that H4K20 marks were indeed enriched in the imprint control region as described before,21 and that H4K20Me3 mark was reduced at the imprint control region in cells expressing mutant PREX2 compared to wildtype controls (Fig. 3A). To further quantify these results, we performed qPCR analysis of the H4K20Me3 levels in the ICR locus which showed consistent reduction of this methylation mark in PREX2 mutant samples (Fig. 3B).
In summary, our study demonstrated the oncogenic capacity of truncating PREX2 mutations in vivo. We identified a direct link between an established oncogenic signaling pathway i.e the PI3K/AKT pathway and provided insights into the downstream regulation of cell growth regulators p57 and IGF2, in melanoma pathogenesis (Fig. 4). However, a number of important outstanding questions remain. Atomic level X-ray structures of full length and truncated PREX2 protein in complex with its substrate will be of great help in elucidating the molecular basis of PREX2 GEF activation. Our understanding of the role of RAC1 in activation of the PI3K/AKT pathway is still rudimentary and need to be explored in greater depth using biochemical, genetic and pharmacologic tools. A further interesting research question is how PREX2 protein stability is affected by the PI3K signaling. What is the ubiquitin ligase that targets PREX2 for degradation? Is it regulated by PI3K/AKT mediated phosphorylation? Finally, even though we have shown 2 major epigenetic marks to be altered in PREX2 mutant cells, we still do not know the direct molecular link between PREX2 and these changes. Are any of the DNA or histone methylatransferases or histone demethylases phosphorylated by PI3K/AKT? Does PI3K, AKT, PTEN or PREX2 interact with H4K20 methyltransferases such as Suv420h1/2? Research to identify the molecular link between changes in the RAC1-PI3K/AKT pathway and downstream epigenetic and gene expression changes is an exciting future endeavor which could have potential translational benefits.
The generation of human primary melanocytes (PMEL/hTERT/CDK4(R24C)/P53DD with either NRASG12D or BRAFV600E have been previously described.22 These cells were grown in Ham's F10 medium (Invitrogen), containing 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin. 293FT cells were grown in DMEM (Invitrogen) containing 10% FBS. We generated MEFs from embryonic day 13.5 (E13.5) embryos using standard methods following PTENL/L, Rosa26-CreERT2 mouse intercrosses. MEFs were grown in DMEM (Invitrogen) containing 10% FBS and 1% penicillin/streptomycin.
Freshly isolated PTENL/L, Rosa26-CreERT2 MEFs were treated once with 1µM 4-hydroxytamoxifen. Whole cell extracts and RNA were isolated from these early passage MEFs (passage 3). This results in partial PTEN depletion. MEFs were treated with BKM120, BEZ235 or MG132 at various concentrations in DMSO for indicated times for time course experiments.
Cells were lysed in lysis buffer (20 mM Tris-HCl, pH 8.0, 150 mM NaCl, 2 mM EDTA, 1% NP40) containing protease and phosphatase inhibitor cocktail tablets (Roche) on ice. Lysates were subjected to denaturation by boiling in SDS-loading buffer (BioRad). Lysates were then loaded on SDS-PAGE gels (BioRad) and transferred using BioRad Turbo semidry transfer system to nitrocellulose membranes which were probed with respective antibodies: PREX2 antibodies (1:1000, Sigma-Aldrich or monoclonal antibody from Abcam), PTEN (1:1000), phospho-Akt S475 (1:1000,Cell Signaling), vinculin (1:5000)
Cells (5 million per antibody) were crosslinked using 1% paraformaldehyde for 10 mins at 37 degrees. Reaction was quenched by 0.125 M glycine for 5 mins, cells washed with PBS and stored at −80°C. Next day cells were thawed on ice and lysed with RIPA buffer (10 mM Tris-HCl pH 8.0, 1 mM EDTA pH 8.0, 140 mM NaCl, 1% Triton x-100, 0.1%SDS, 0.1% DOC) for 10 min on ice. Sonication was performed using Branson Sonifier 250 to achieve shear length of 300–600 bp. Extracts were then incubated overnight with respective antibody-dynabead mixture that were incubated separately for 1 hr at 4°C earlier [Rabbit IgG, H4K20me1, H4K20me2, H4K20me3 (ALL Abcam)]. Immunecomplexes were then washed 5 times with RIPA buffer, once with RIPA-500 (RIPA with 500 mM NaCl) and once with LiCl wash buffer (10 mM Tris-HCl pH 8.0, 1 mM EDTA pH 8.0, 250 mM LiCl ,0.5% NP-40 ,0.5% DOC). Elution and decrosslinking was performed in direct elution buffer (10 mM Tris-Cl pH 8.0, 5 mM EDTA, 300 mM NaCl, 0.5% SDS) by incubating immunecomplxes at 65°C for 4–16 hrs. Proteinase K (20 mg/ml) and RNaseA treatment was performed and DNA cleaned up using SPRI beads (Beckman-Coulter). Library preparation was done using NEBNext ChIP-Seq library preparation kit per manufacturer's instructions. Illumina paired end adapters were used. Sequencing was performed in Hiseq2000 (Illumina).
ChIP was done as described above. Next quantitative PCR for 2 regions (R1 and R2; R1 being test region at KCNQ1OT1 locus and R2 being negative region showing no enrichment in ChIP-Seq) was performed on ChIP DNA (H4K20me3) using SYBR Greener reagent and Stratagene Mx3005p instrument. Relative enrichment on R1 normalized to values on R2 are shown.
Primer information is shown below:
H4K20ME ChIP-Seq reads were aligned using Bowtie (version 1.0.0)23 to human genome assembly NCBI Build 37 (UCSC hg19) with the following parameters: -n 1 -m 1 –best –strata (uniquely mapped reads with one mismatch were retained).
Enriched regions were detected by Scripture package20 with varying window sizes (750,1500,5000), and peaks were defined whose coverage at 0.05 significance.24 Collapsed repeat regions in the human genome25 and “ultra-high signal suspect regions” identified by ENCODE project26 (https://docs.google.com/spreadsheet/ccc?key=0Am6FxqAtrFDwdE5LYWh2MkVscmtCWEdtNUN2eEVEYmcandhl=en#gid=5) were masked during the peak calling procedure. Called regions were merged with BEDTools.27 Intervals with less than 350 base pair length and enriched regions in whole cell extract samples were excluded from the final list. Sequences were extended to 200 bp and average read counts were calculated in 25 bp bins. Total read numbers were normalized to 10 million reads for each sample and these values used for the following analyses.
Aggregate plots were generated using the NGSplot toolbox (https://code.google.com/p/ngsplot/) around GFP-Me3 binding sites. Box plots were generated calculating RPKM values around GFP-Me3/2/1 enriched regions for each sample. Wilcoxon test was applied to compare conditions.
No potential conflicts of interest were disclosed.